全文获取类型
收费全文 | 4039篇 |
免费 | 254篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 38篇 |
儿科学 | 123篇 |
妇产科学 | 36篇 |
基础医学 | 378篇 |
口腔科学 | 108篇 |
临床医学 | 323篇 |
内科学 | 955篇 |
皮肤病学 | 57篇 |
神经病学 | 284篇 |
特种医学 | 139篇 |
外科学 | 802篇 |
综合类 | 81篇 |
一般理论 | 1篇 |
预防医学 | 164篇 |
眼科学 | 142篇 |
药学 | 363篇 |
1篇 | |
中国医学 | 15篇 |
肿瘤学 | 291篇 |
出版年
2023年 | 38篇 |
2022年 | 33篇 |
2021年 | 183篇 |
2020年 | 92篇 |
2019年 | 141篇 |
2018年 | 169篇 |
2017年 | 139篇 |
2016年 | 153篇 |
2015年 | 163篇 |
2014年 | 223篇 |
2013年 | 265篇 |
2012年 | 372篇 |
2011年 | 389篇 |
2010年 | 224篇 |
2009年 | 198篇 |
2008年 | 267篇 |
2007年 | 250篇 |
2006年 | 175篇 |
2005年 | 222篇 |
2004年 | 182篇 |
2003年 | 142篇 |
2002年 | 116篇 |
2001年 | 28篇 |
2000年 | 13篇 |
1999年 | 15篇 |
1998年 | 16篇 |
1997年 | 6篇 |
1996年 | 4篇 |
1995年 | 9篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 8篇 |
1991年 | 6篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 5篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1927年 | 1篇 |
排序方式: 共有4301条查询结果,搜索用时 31 毫秒
1.
2.
The advent of precision medicine has changed the landscape of oncologic biomarkers, drug discovery, drug development, and, more importantly, outcomes for patients with cancer. Precision oncology entails the genomic profiling of tumors to detect actionable aberrations. The advances in clinical next-generation sequencing from both tumor tissue and liquid biopsy and availability of targeted therapies has rapidly entered mainstream clinical practice. In this review, recent major developments in precision oncology that have affected outcomes for patients with cancer are discussed. Rapid clinical development was seen of targeted agents across various mutational profiles such as KRASG12C (which was considered “undruggable” for almost 4 decades), Exon 20 insertions, and RET mutations. Approaches to precision chemotherapy delivery by the introduction of antibody drug conjugates in the armamentarium against lung cancer has been appreciated. 相似文献
3.
4.
Roberto V.P. Ribeiro Mitesh V. Badiwala Danny Ramzy Laura C. Tumiati Vivek Rao 《The Journal of thoracic and cardiovascular surgery》2019,157(2):615-625.e1
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献5.
6.
7.
8.
Inflammation Research - Gallic acid (GA) a naturally occurring phenolic compound, known to possess antioxidant/anti-inflammatory activities. The aim of the present work was to investigate the... 相似文献
9.
Ryosuke Ono Michio Yagi Akinobu Shoji Kayo Fujita Mizuki Yoshida William C. Ports Vivek S. Purohit 《The Journal of dermatology》2020,47(1):25-32
Crisaborole ointment, 2%, is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis (AD). This parallel-cohort, phase 1 study was conducted to investigate skin irritation potential and safety of crisaborole in healthy Japanese adults (cohort 1) and the safety and pharmacokinetic profile of crisaborole and metabolites AN7602 and AN8323 in Japanese adults with mild to moderate AD (cohort 2). In cohort 1, 20 healthy volunteers received single applications of crisaborole and vehicle simultaneously on separate locations under 48-h occlusion. In cohort 2, 12 patients with mild to moderate AD received crisaborole (n = 10) or vehicle (n = 2) twice daily for 8 days. Skin irritation and safety were assessed in cohort 1. Pharmacokinetics and safety were assessed in cohort 2. Skin irritation index (scale 0–400) was 40.0 for crisaborole and 5.0 for vehicle. No treatment-emergent adverse events (TEAE) were reported in cohort 1. The most common TEAE in the crisaborole group in cohort 2 were application site irritation (n = 7) and application site pain (n = 4). Crisaborole was rapidly absorbed, with limited systemic exposure between days 1 and 8 that was comparable with that seen in US-based participants in previous trials. Crisaborole had higher skin irritation than vehicle under occlusion in healthy Japanese adults and had an acceptable safety profile in Japanese adults with mild to moderate AD. 相似文献
10.
Vivek Ashoka Menon Elissa Tong Dana Rose-Marie Louise Slape Tai Anh Phan Renee CF Chan 《The Australasian journal of dermatology》2020,61(1):e97-e99
Dermatitis artefacta is a self-inflicted cutaneous disease presenting as sharply delineated ulcers, usually in accessible sites such as the head and neck. IgG4-related disease (IgG4-RD) is a recently recognised immune-mediated condition causing a fibroinflammatory process, resulting in the formation of tumefactive lesions in various organs, rarely presenting primarily in the skin. We report a case of cutaneous IgG4-RD clinically presenting as dermatitis artefacta. 相似文献